"End of January, the Company also plans to request a meeting with the United States (“US”) Food & Drug Administration (“FDA”) in order to explore the possibility of a change from PIND to IND status and approving Escozine for a 30-to-60 patient pilot study to show proof of concept within the US." $QNTA
ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.